Paris I - Search Results

1

Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study).

Nero C, Ciccarone F, Boldrini L, Lenkowicz J, Paris I, Capoluongo ED, Testa AC, Fagotti A, Valentini V, Scambia G. Nero C, et al. Among authors: paris i. Sci Rep. 2020 Oct 5;10(1):16511. doi: 10.1038/s41598-020-73505-2. Sci Rep. 2020. PMID: 33020566 Free PMC article.

2

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.

Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P, Elvevi A, Uguccioni M; NetworkER+. Cazzaniga ME, et al. Breast Cancer Res Treat. 2019 Aug;176(3):483-494. doi: 10.1007/s10549-019-05261-5. Epub 2019 May 7. Breast Cancer Res Treat. 2019. PMID: 31065872 Free PMC article. Review.

3

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.

Cazzaniga ME, Ciaccio A, Danesi R, Duhoux FP, Girmenia C, Zaman K, Lindman H, Luppi F, Mavroudis D, Paris I, Olubukola A, Samreen A, Schem C, Singer C, Snegovoy A. Cazzaniga ME, et al. Among authors: paris i. Front Oncol. 2023 Oct 26;13:1247270. doi: 10.3389/fonc.2023.1247270. eCollection 2023. Front Oncol. 2023. PMID: 37954071 Free PMC article.

4

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.

Ferrandina G, Paris I, Ludovisi M, D'Agostino G, Testa A, Lorusso D, Zanghi M, Pisconti S, Pezzella G, Adamo V, Breda E, Scambia G. Ferrandina G, et al. Among authors: paris i. Gynecol Oncol. 2005 Aug;98(2):267-73. doi: 10.1016/j.ygyno.2005.04.018. Gynecol Oncol. 2005. PMID: 15975643 Clinical Trial.

5

Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.

Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A, Scambia G. Fagotti A, et al. Among authors: paris i. Gynecol Oncol. 2009 Jun;113(3):335-40. doi: 10.1016/j.ygyno.2009.03.004. Epub 2009 Apr 5. Gynecol Oncol. 2009. PMID: 19345401 Clinical Trial.

6

Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.

Petrillo M, Paris I, Vizzielli G, Amadio G, Cosentino F, Salutari V, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S952-8. doi: 10.1245/s10434-015-4651-8. Epub 2015 Jun 3. Ann Surg Oncol. 2015. PMID: 26036187

7

Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.

Petrillo M, Amadio G, Salutari V, Paris I, Di Stefano MG, Ferandina G, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Gynecol Oncol. 2016 Aug;142(2):231-6. doi: 10.1016/j.ygyno.2016.05.017. Epub 2016 May 26. Gynecol Oncol. 2016. PMID: 27215633

8

Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.

Concolino P, Rizza R, Hackmann K, Paris I, Minucci A, De Paolis E, Scambia G, Zuppi C, Schrock E, Capoluongo E. Concolino P, et al. Among authors: paris i. Breast Cancer Res Treat. 2017 Jul;164(2):497-503. doi: 10.1007/s10549-017-4275-8. Epub 2017 May 9. Breast Cancer Res Treat. 2017. PMID: 28488140

9

BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.

Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A. Petrillo M, et al. Among authors: paris i. Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23. Am J Obstet Gynecol. 2017. PMID: 28549976

10

Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.

Ferrandina G, Amadio G, Paris I, Distefano M, Palluzzi E, de Vincenzo R, Ricci C, Scambia G. Ferrandina G, et al. Among authors: paris i. Int J Gynecol Cancer. 2017 Jul;27(6):1141-1148. doi: 10.1097/IGC.0000000000001058. Int J Gynecol Cancer. 2017. PMID: 28574933

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

166 results

Search Page

Filters